Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

  title={Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus},
  author={Chasity D. Andrews and William R. Spreen and Hiroshi Mohri and Lee Moss and Susan H. Ford and Agegnehu Gettie and Kasi E Russell-Lodrigue and Rudolf P. Bohm and Cecilia Cheng-Mayer and Zhi Hong and Martin Markowitz and David D. Ho},
GSK1265744 (GSK744) is an integrase strand-transfer inhibitor that has been formulated as a long-acting (LA) injectable suitable for monthly to quarterly clinical administration. GSK744 LA was administered at two time points 4 weeks apart beginning 1 week before virus administration, and macaques were challenged weekly for 8 weeks. GSK744 LA, at plasma concentrations achievable with quarterly injections in humans, protected all animals against repeated low-dose challenges. In a second… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 27 times over the past 90 days. VIEW TWEETS
39 Citations
31 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 39 extracted citations


Publications referenced by this paper.
Showing 1-10 of 31 references

HIV Clin Trials

  • W Spreen
  • [PubMed:
  • 2013
Highly Influential
3 Excerpts

Dolutegravir in antiretroviralnaive adults with HIV - 1 : 96week results from a randomized doseranging study

  • A. Rachlis, H. J. Stellbrink, +10 authors S. Min
  • AIDS
  • 2013

Safety and efficacy of dolutegravir in treatmentexperienced subjects with raltegravirresistant HIV type 1 infection : 24 - week results of the VIKING Study

  • D. A. Margolis, J. C. Pottage
  • J . Infect . Dis .
  • 2013

paper presented at the 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA

  • J Marrazzo
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…